Download Oxygen Therapy, Inc. Files S

Oxygen Therapy, Inc. Files S-1
Registration Statement
NEWS PROVIDED BY
Oxygen Therapy, Inc.
November 1, 2016, 09:00 EDT
New York, NY., November 1, 2016/Marketwired/ -- Oxygen Therapy, Inc. (the “Company”), the
developer of innovative oxygen therapies for treating and protecting the brain during and after stroke,
announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange
Commission (the "SEC").
The registration statement has not yet become effective. The securities described in the registration
statement may not be sold by the Company nor may offers to buy or to be accepted by the Company prior
to the time the registration statement becomes effective.
Once the registration statement is declared effective, the subscription period is expected to stay open for
approximately 90 days following the record date.
The Company intends to use the proceeds of this offering for general corporate purposes, which may
include funding for product development, design of clinical trials, marketing, and general working capital
purposes.
This press release shall not and does not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale,
would be unlawful prior to the registration or qualification under the securities laws of any such
jurisdiction.
The offering of the securities described in the registration statement is self-directed.
When available, copies of the prospectus relating to the offering may be obtained from the Company for
the offering:
Yuval Kwintner, President.
202 Lenox Avenue New York, NY 10026
[email protected]
Tel: (646) 454-1384
About Oxygen Therapy, Inc.
Oxygen Therapy Inc. is a biopharmaceutical company that develops anti-necrosis drugs that treat a
variety of medical conditions resulting from ischemia. The Company focuses on the development and
commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from
hypoxic conditions following brain stroke also known as Cardiac Cerebrovascular Accidents (CVA). The
Company’s lead product candidate, OTI-629, is an anti-necrosis drug that carries oxygen to brain tissues
when the flow of blood is blocked. For more information, visit www.otipharma.com
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Oxygen
Therapy, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions
of the future are forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the Company's actual results could differ materially from
those in any such forward-looking statements. Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the company's cash flow, market acceptance
risks, and technical development risks. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release. Oxygen Therapy, Inc. disclaims any
obligation, and does not undertake to update or revise any forward-looking statements in this press
release.
SOURCE: Oxygen Therapy, Inc.
Related Links http://www.otipharma.com